PATENT CLAIM ANALYSIS

Application Number: 15989405
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["424", "184100"]

Abstract:
A method to prevent, inhibit or treat one or more symptoms associated with a disease of the central nervous system by intrathecally, intracerebroventricularly or endovascularly administering a rAAV encoding a gene product associated with the disease, e.g., a mammal in which the gene product is absent or present at a reduced level relative to a mammal without the disease.

Claim (Index 12):
The method of  claim 9  wherein the immune suppressant comprises a nitrogen mustard, nitrosourea, platinum compound, methotrexate, azathioprine, mercaptopurine, fluorouracil, dactinomycin, an anthracyclin e, mitomycin C, bleomycin, mithramycin, IL-2 receptor-(CD25-) or CD3-directed antibodies, anti-IL-2 antibodies, ciclosporin, tacrolimus, sirolimus, IFN-beta, IFN-gamma, an opioid, or a TNF-alpha (tumor necrosis factor-alpha) binding agent.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 93.0
- Lexical Diversity: 1.52381
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14889750', '13465575', '14103597', '11057410', '14769596']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7780885133503158
- 35 USC 102 Novelty (BERT): 0.7399097255371936
- Combined Prediction Score: 0.7742706345690036
- Mean Citation Score: 470.665054
- Max Citation Score: 768.5469400000003
- Similarity Product: 749.3636561689415

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test